Matrix Metalloproteinase-activated Anthrax Lethal Toxin Demonstrates High Potency in Targeting Tumor Vasculature
Open Access
- 1 January 2008
- journal article
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 283 (1) , 529-540
- https://doi.org/10.1074/jbc.m707419200
Abstract
No abstract availableKeywords
This publication has 42 references indexed in Scilit:
- Anthrax Protective Antigen Cleavage and Clearance from the Blood of Mice and RatsInfection and Immunity, 2007
- Systemic Anthrax Lethal Toxin Therapy Produces Regressions of Subcutaneous Human Melanoma Tumors in Athymic Nude MiceClinical Cancer Research, 2006
- Characterization of the interaction between anthrax toxin and its cellular receptorsCellular Microbiology, 2006
- The NCI60 human tumour cell line anticancer drug screenNature Reviews Cancer, 2006
- BRAF mutation predicts sensitivity to MEK inhibitionNature, 2005
- Mutations of the BRAF gene in human cancerNature, 2002
- New functions for the matrix metalloproteinases in cancer progressionNature Reviews Cancer, 2002
- Cutaneous Wound HealingNew England Journal of Medicine, 1999
- Anthrax Lethal Factor Cleaves the N-Terminus of MAPKKs and Induces Tyrosine/Threonine Phosphorylation of MAPKs in Cultured MacrophagesBiochemical and Biophysical Research Communications, 1998
- Tumors: Wounds That Do Not HealNew England Journal of Medicine, 1986